Clinical Trial

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-06-02; most recent amendment 2026-04-07.
Status change: Enrolling by Invitation → Active, Not Recruiting 2026-04-07
Status change: Not Yet Recruiting → Enrolling by Invitation 2021-08-26
Trial Details
NCT Number NCT04911478
Lead Sponsor Adicet Therapeutics
Conditions Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Enrollment 50 participants
Start Date 2022-02-14
Primary Completion 2038-08 (estimated)
Study Completion 2039-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-09